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The entire world is looking for effective cancer therapies whose benefits would outweigh their toxicity. One way to reduce 
resistance to chemotherapy and its adverse effects is the so called targeted therapy, which targets specific molecules 
(“molecular targets”) that play a critical role in cancer growth, progression, and metastasis. One such specific target are 
microtubules. In this review we address the current knowledge about microtubule-targeting agents or drugs (MTAs/MTDs) 
used in cancer therapy from their synthesis to toxicities. Synthetic and natural MTAs exhibit antitumor activity, and 
preclinical and clinical studies have shown that their anticancer effectiveness is higher than that of traditional drug 
therapies. Furthermore, MTAs involve a lower risk of adverse effects such as neurotoxicity and haemotoxicity. Several 
new generation MTAs are currently being evaluated for clinical use. This review brings updated information on the 
benefits of MTAs, therapeutic approaches, advantages, and challenges in their research.
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Cancer is a multifactorial disease that invades adjoining 
parts of the body and spreads to other organs (1). Cancer 
cells lack normal genetic regulation and often have 
mutations in one or more mitotic checkpoints or mitotic 
errors which are not properly detected/repaired due to 
mutations in the cellular machinery (2).
The aim of common cancer therapies (chemotherapy, 
radiation therapy, or surgery) is to effectively destroy cancer 
cells without harming normal cells or tissues (3). Among 
them, chemotherapy has been the most common –ever since 
the 1940s, when the first widely used cancer drug, called 
nitrogen/sulphur mustard, was discovered. However, 
chemotherapeutic agents have undesirable adverse effects, 
as they cannot distinguish between normal and cancer cells.
The idea behind targeted therapy is to minimise the 
adverse effects by targeting parts of cancer cells that 
distinguish cancer from normal.
This review focuses on one such targeted therapy with 
microtubule-targeting agents (MTAs), first introduced into 
clinical use in the late 1950s. Fundamentally, MTAs induce 
mitotic arrest through interference with intracellular 
transport and suppression of microtubule dynamics, 
resulting in cytotoxicity (4).
FUNCTIONS OF MICROTUBULES
Microtubules are involved in a number of cellular 
processes, such as the maintenance of cell shape, division, and 
migration, intracellular transport, and endothelial cell biology 
(5). They play a crucial role in the assembly of the spindle 
apparatus and right segregation of chromosome (6, 7).
Their crucial involvement in the formation of mitotic 
spindles during cell division makes them an attractive target 
for cancer therapy.
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MECHANISMS OF ACTION OF MTAs
MTAs act against mitosis by interacting with tubulins 
at different sites (Figure 1) (6) and interfering with the 
spindle dynamics. According to the mechanism of action, 
they are traditionally divided in two major groups: 
microtubule-stabilising (MSAs) and microtubule 
destabilising agents (MDAs). MSAs, such as taxanes (8), 
epothilones (9), and laulimalide (10) promote and stabilise 
tubulin polymerisation, whereas MDAs do the opposite. 
They prevent tubulin polymerisation and promote 
depolymerisation. Disassembly promoters bind to either 
the colchicine domain at the intradimer interface between 
α- and β-tubulin or the vinca domain near the exchangeable 
GTP-binding site (E-site) on β-tubulin (11). This group 
includes colchicines (12), vinca alkaloids (13), eribulin, 
nocodazole (14), and combretastatin A-4 (CA-4) (11, 15).
Regardless of different binding sites, most MTAs elicit 
remarkably similar effects on microtubules, especially at 
the lowest effective drug concentrations. Taxanes bind to 
polymerised microtubules at the inner surface of the β 
subunit and stimulate tubulin polymerisation (8). Similarly, 
epothilones bind to the taxane pocket of β-tubulin (16). 
Colchicine, in turn, binds tubulin and blocks polymerisation 
(12). Vinca alkaloids (vinblastine, vincristine) cause 
depolymerisation by forming tubulin paracrystals (6). 
Laulimalide and peloruside also bind to a non-taxane site 
between two β-tubulins and promote the assembly of 
microtubules (17, 18) by strongly modulating longitudinal 
interactions between tubulin dimers and moderately 
modulating lateral interactions (2). Eribulin inhibits tubulin 
polymerisation by binding the interdimer interface or the 
β-tubulin subunit. It also sequesters tubulin monomers into 
non-functional aggregates (13). Nocodazole interferes with 
the polymerisation of microtubules (14).
STUDIES ON MTAs: FROM MOLECULE TO 
DRUG
Small organic molecules which disrupt microtubule/
tubulin dynamics have been used in cancer therapy for many 
years, and new small organic molecules with antitubulin 
activity are being studied and developed (19).
Combretastatin A-4 derivatives
Combretastatin is a natural product isolated from 
Combretum caffeum grown in South Africa. CA-4 and its 
analogues (Figures 2 and 3) are potent antitumour agents 
with demonstrated biological activity (20–23). CA-4 has 
low water solubility, but this problem has been solved with 
water-soluble derivatives. Recent studies (24) report that 
CA-4 causes 90–99 % tumour necrosis, and phase III 
clinical trials with CA-4 evidence that CA-4P is effective 
and safe in the treatment of thyroid cancer (25).
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Figure 1 Inhibition of microtubule polymerisation and depolymerisation by MTAs.Taxanes bind to inner surface and plus ends of 
microtubule; Colchicines bind to β-tubulin in the outer surface of the microtubule; Vinca alkaloids bind to β-tubulin in the outer 
surface of the microtubule and to tubulin dimers;  Nocodazole binds to tubulin dimers; Eribulin binds to β-tubulin in the microtubule 
end and to tubulin dimers; ▲Laulimalide and peloruside bind to β-tubulin in the outer surface of the microtubule (laulimalide binding 
site); Epothilone binds to β-tubulin in the outer surface of the microtubule (near the taxane-binding site); Combretastatin A4 
binds to the colchicine-binding site
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Colchicine derivatives
Colchicine is obtained from Colchicum autumnale by 
extraction. It strongly binds to tubulin and disturbs 
microtubule assembly dynamics. Due to its toxicity, 
research has been focused on less toxic colchicine 
derivatives (Figure 4) (26, 27).
Indole derivatives
In recent years, a number of pharmacological activity 
studies have been focused on compounds bearing indole 
structure and reported antitumour activity through inhibition 
of tubulin polymerisation. Indole has also provided one of 
the most important skeletons for CA-4 analogues (28–32). 
Figure 5 shows some examples of MTAs with indole 
backbone (compounds 12–18) (33–39).
Other MTAs
Heterocyclic compounds such as 5-flourouracil, 
methotrexate, doxorubicin, and daunorubicin exhibit 
anticancer properties and have always made the core of 
anticancer drugs (40).
Flavonoids and isoflavonoids are natural oxygen 
heterocyclic compounds carrying a benzopyran-4-one 
building block. The biological activity of flavonoids and 
isoflavonoids changes with the position of the phenyl ring. 
Flavonoids have the benzopyran-4-one core with a phenyl 
ring at position 2, and isoflavonoids at position 3. 
Flavonoids with anticancer activity include baicalein and 
quercetin, which have a 2-arylbenzopyran-4-one 
pharmacophore group. Tambulin (3,5-dihydroxy-7,8-
dimethoxy-2-(4-methoxyphenyl)benzopyran-4-one) is 
isolated from the fruits of Zanthoxylum armatum and used 
as a starting material for the synthesis of alkyl amine 
derivatives (Figure 6, compound 19) (41).
Shikonin is isolated from the root of Lithospermum 
erythrorhizon and has been used in Europe and Asia since 
antiquity (42). This natural compound has many 
pharmacological properties, such as wound healing, 
antioxidant, antibacterial, anti-inflammatory, and antitumour 
(43–47). Structural changes have been made to increase 
target specificity, since shikonin shows non-selective 
cytotoxic effects on normal cells. One such compound is 
chalcone-containing shikonin derivative (48) (Figure 6, 
compound 20).
ABT-751 (Figure 6, compound 21) is an oral synthetic 
antimitotic sulphonamide. It binds to the colchicine-binding 
site on β-tubulin and inhibits the polymerisation of 
microtubules. This, in turn, stops the cell cycle at the G2/M 
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Figure 2 CA-4 (with pharmacophore groups) and CA-4P  structure
Figure 3 Some of the novel CA-4 analogues; TPI – tubulin polymerisation inhibition
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phase and cellular apoptosis and prevents tumour cell 
replication. ABT-751 has been evidenced a significant 
anticancer effect against non-small cell lung cancer 
(NSCLC) and colon cancer (49–52). Elmeligie et al. (53) 
synthesised a series of new 3-substituted-2-(4-
hydroxyanilino) pyridine derivatives structurally related to 
ABT-751. They evaluated their cytotoxicity using inhibitory 
a c t i v i t y  o f  t u b u l i n  p o l y m e r a s e  ( F i g u r e  6 ) . 
4-[3-[5-(4-methoxyphenylamino)-1,3,4-oxadiazol-2-yl] 
pyridin-2-ylamino] phenol (compound 22) also showed 
high inhibitory activity.
Moving from the structure of ABT-751, Liu et al. (54) 
s y n t h e s i s e d  7 - s u b s t i t u t e d  1 - m e t h y l - 1 , 4 -
dihydroindeno[1,2-c] pyrazole (compound 23) as a potential 
tubulin polymerisation inhibitor by targeting a new binding 
region at the interface between α and β-tubulin heterodimers 
at the colchicine binding site. Pyrazole aldehydes (4a-d), 
Knoevenagel’s condensates (5a-d), and Schiff’s bases (6a-
d) of curcumin-I were also synthesised, and analysed for 
haemolysis, cell line activities, DNA binding and docking. 
These compounds were less haemolytic than standard drug 
doxorubicin (55).
Metal-based drugs such as cisplatin have commonly 
been used in cancer therapy. However, due to severe toxicity 
of platinum drugs, research focus has shifted to the synthesis 
of new, less toxic drugs. An example is pyrazoline-based 
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Figure 4 Small molecules derived from colchicine
Figure 5 Some recent compounds with an indole backbone structure
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ligand [5-(4-chlorophenyl)-3-(4-fluorophenyl)-4,5-dihydro-
1H-pyrazole-1-carbothioamide] and its complexes with 
copper(II), nickel(II), and iron(III) metal ions. In silico and 
DNA binding studies suggest that these agents have good 
DNA binding ability, which is an important prerequisite for 
effective anticancer drugs (56).
Magalhase et al. (57) designed and synthesised acridin-
8-one derivatives (compound 24), inspired by the structure 
of podophyllotoxin. Podophyllotoxins are natural agents 
which bind to the colchicine-binding site with remarkable 
inhibitory activity on microtubule assembly.
There are also reports of the design, synthesis, and 
biological evaluations of novel 4-substituted 5-methyl-
furo[2,3-d] pyrimidines (58). Compound 25 (Figure 6) is 
an important candidate for further research and development. 
It is currently under preclinical evaluations.
NATURAL COMPOUNDS
Taxol, a taxanediterpenoid, is widely used in the 
treatment of a variety of cancers (breast, ovarian, lung, head, 
and neck) (5, 60). Taxanes promote tubulin stabilisation by 
straightening GDP-tubulin protofilaments into a 
conformation resembling GTP-tubulin (61, 62).
So far, more than 400 taxanes have been isolated from 
several Taxus species (63), including N-debenzoyl-N-
methyl-N-heptanoyl-taxol (compound 26), N-debenzoyl-
N-methyl-N-octanoyl-taxol (compound 27), N-debenzoyl-
N-methyl-N-(4-methylhexanoyl)-axol (compound 28), and 
N-debenzoyl-N-methyl-N-[(4Z)-1-oxo-4-tenenoyl]taxol 
(compound 29) (Figure 7) identified in Taxus wallichiana 
var. mairer (64). Their antitumor activities were evaluated 
in different cancer lines (MCF-7, A549, and 3-AO). 
Compound 28 showed a significant antitumor activity on 
the MCF-7 cell line, with anticancer effect similar to taxol, 
which was used as positive control. In fact, compound 28 
has been reported as a promising anticancer agent in breast 
cancer therapy. Compounds 26, 27, and 29 showed lower 
cytotoxicity than paclitaxel. All of them also exhibited a 
change/shift in microtubule dynamics similar to that of 
paclitaxel.
The microtubule cytoskeleton is the main target of 
paclitaxel (65). This drug interacts with the β-subunit of 
polymerised  microtubules  and prevents  the i r 
depolymerisation, which, in turn, results in mitotic arrest 
and apoptosis. Verma et al. (66) tried to identify a potent 
β-tubulin inhibitor using experimental and in silico 
approaches. For this purpose, compounds were extracted 
from Cassia fistula and their structure identified by GC-MS. 
Subsequently, oral bioavailability, toxicity, and docking 
studies resulted in one promising inhibitor molecule, namely 
Hop-22(29)-en-3. beta-ol (Figure 8). The results of in silico 
studies suggest that it binds effectively to both the native 
and mutant β-tubulin. Its bioavailability was significantly 
higher than that of paclitaxel. However, these results need 
confirmation from experimental findings.
Searching the Naturally Occurring Plant-based Anti-
cancer Compound-Activity-Target (NPACT) database, 
Verma et al. (66) identified 1574 alkaloids with anticancer 
potential. Their pharmacokinetics and toxicity, binding 
efficiency, binding affinity of the docked complex, and 
metabolising capacity were evaluated by several computer 
programs. The results of these computational analyses 
suggest, for the first time, that isostrychnine isolated from 
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Figure 6 Miscellaneous derivatives synthesised and evaluated as MTAs
165
Strychnosnux-vomica might have an inhibitory potential 
against β-tubulin, but this has yet to be confirmed 
experimentally.
Stillingias anguinolenta is an endemic Mexican medical 
plant with many unusual cyclic organic compounds (67). 
About 30 Stillingia species are used as folk medicines for 
different purposes in America. In a recent study, Pfeffer et 
al. (68) reported inhibitory activity on kinesin-5 mitotic 
motor molecules by tonantzitlolone A (Figure 9, compound 
30), a diterpene isolated from Stillingias anguinolenta, and 
by its synthetic enantiomer (compound 33). Both promote 
microtubule polymerisation by reducing the attachment of 
kinesin-5 molecules to microtubules, increasing, in turn, 
the growth rate and decreasing the mitotic catastrophe 
frequency. The synthetic enantiomer showed a stronger 
inh ib i tory  e ffec t  than  the  na tura l  compound 
(IC50~44.5 mmol/L versus IC50~147 mmol/L, respectively). 
This inhibitory effect is related to the chemical modification 
of the parent molecule responsible for the enhanced 
antiproliferative effect of the natural compound 
tonantzitlolone A.
Magnolol, a hydroxylated biphenyl compound, is 
isolated from Magnolia officinalis (Magnoliaceae). It has 
muscle relaxant, antioxidant, anti-atherosclerotic, anti-
inflammatory, and antimicrobial effects. It is widely used 
as a folk remedy, especially in the Far East (69). In recent 
years, it has been studied for anticancer effects (70–72) and 
reported to suppress metastasis in PC-3 human prostate 
carcinoma cells (70). Its wnt/beta-catenin signalling 
pathway has been shown to mediate anticancer effect (71). 
Magnolol has also been tested for cancer growth inhibition 
and shown to use the p53 pathway to suppress the 
development of cancer in gallbladder cancer cells (72). Shen 
et al. (73) tested its effect on cellular microtubule 
polymerisation in human non-small lung cancer cells. Its 
IC50 of approximately 5 µmol/L at 72 h makes it a promising 
candidate for the treatment of NSCLC.
Thalicthuberine, a phenanthrene alkaloid isolated from 
Hernandia albiflora (Hernandiaceae), is known for its 
antimicrobial activity (74). Levrier et al. (75) examined its 
antimitotic activity in prostate (PC-3) and cervical cancer 
(HeLa) cells and established respective IC50of 0.7 and 
2.5 mmol/L. This promising agent did not directly inhibit 
tubulin polymerisation, but it destroyed cellular tubulin 
polymers and suppressed mitotic spindle dynamics.
6α-acetoxyanopterine (6-AA) is one of the anopterine 
analogues isolated from the Australian endemic tree Anopterus 
macleayanus. Levrier et al. (76) reported that 6-AA inhibited 
cell growth in prostate cell lines (IC50=3.1–11. 5 nmol/L). The 
same authors compared 6-AA activity with well-known 
microtubule inhibitors such as taxanes, vinca alkaloids, and 
2-methoxyestradiol (2ME2) (Figure 10) to find a number 
of promising effects (77). At low, nanomolar, concentrations 
Karahalil B, Yardım-Akaydin S, Nacak Baytas S. An overview of microtubule targeting agents for cancer therapy 
Arh Hig Rada Toksikol 2019;70:160-172
Figure 7 Structures of N-debenzoyl-N-methyl-N-heptanoyl-taxol[27], N-debenzoyl-N-methyl-N-octanoyl-taxol[28], N-debenzoyl-N-
methyl-N-[4-methylhexanoyl]-axol[29], and N-debenzoyl-N-methyl-N-[[4Z]-1-oxo-4-tenenoyl]taxol[30]
Figure 8 Structure of HOP-22(29)-EN-3
Figure 9 Structures of tonantzitlolone A [30] and B [31], and schematic representation of the flexibilane backbone [32], [ent]-
tonantzitlolone A [33]
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6-AA caused a strong accumulation of androgen-sensitive 
human prostate adenocarcinoma (LNCaP) cells in mitosis 
[through increased levels of phospho-Ser10 histone 3 
protein (PHH3), which is a marker of mitosis], severe 
mitotic spindle defects, and asymmetric cell divisions in 
both prostate and cervical cancer cells. 6-AA caused mitotic 
catastrophe and cell death by apoptosis due to cell 
accumulation in the G2/M phase and deregulation of mitotic 
pathways. It also turned out to be a reversible microtubule-
destabilising molecule at nanomolar concentrations, which, 
unlike vinca alkaloids and 2ME2, directly interacted with 
tubulin.
Anticancer activity of polycyclic fatty acids contained 
in the plants of the genus Beilschmiedia has also been 
investigated. Williams et al. (78) collected plant materials 
in Nyanga (Gabon) and isolated one major component, 
neolignan iso-ocobullenone (Figure 11, compound 34), and 
a number of other minor components (Figure 11). Their 
cytotoxicity was screened with nuclear magnetic resonance 
(NMR) spectroscopy in NCI-H460 human lung cancer cells. 
Nine compounds had IC50 over 20 μg/mL; 11 between 20 
and 1 μg/mL, and only one, neolignan bifidenone (Figure 
11, compound 35), had the IC50 of 0.26 μmol/L. It also 
showed high antiproliferative activity in other cancer cells, 
including melanoma cell lines (A375, UACC-62, and SK-
Mel-2) and the first NCI-60-cell line (IC50 of 0.27 μmol/L), 
but not as high in the HCC-2998 colorectal cell line (IC50 
1.41 μmol/L). The most sensitive cell lines (IC50<0.1 μmol/L) 
turned out to be SR lymphoblasts and the MALME-3M and 
MDA-MB-435 melanoma cells.
Mukhtar et al. (79) reported that compound 35 inhibited 
tubulin polymerisation in a dose-dependent manner, arrested 
the cell cycle in the G2/M phase, and competed for the 
colchicine binding site.
ADVERSE EFFECTS OF MTAs
Haematological and gastrointestinal toxicity
Haematological toxicities of MTAs are usually related 
to neutropenia and myelosuppression. Myelosuppression 
results from the inhibition of rapidly dividing hematopoietic 
cells. Neutropenia is a more serious and usually dose-
limiting factor (80).
Neurological toxicity
In addition to these adverse effects, clinical trials of a 
new epothilone class of MTAs (such as ixabepilone and 
sagopilone, analogous to taxanes) reported neurotoxicity, 
which diminished with lowering the dose, but this resulted 
in higher gastrointestinal toxicity (81).
A major limitation to the use of MTAs is the high rate 
of neuropathy. Microtubule integrity is critical to normal 
neuronal function, and any microtubule dysfunction can 
lead to the development of some form of neuropathy 
through disruption of axonal transport and function (82).
Peripheral neuropathy (PN) is a result of damage to 
peripheral nerves. It is a prominent dose-limiting adverse 
effect of paclitaxel (83). This drug induces microtubule 
aggregation in the peripheral nervous system and interrupts 
axonal transport. Severe PN is less common in patients 
treated with docetaxel. However, there is no reliable 
objective method to assess PN, and PN diagnosis relies on 
clinical assessment, including physical examination (84).
CHALLENGES
Although many MSAs have been applied extensively 
in clinical settings, the use of paclitaxel and other approved 
MSAs still presents many challenges, such a slow passage 
through the blood-brain barrier (BBB), poor solubility, 
toxicity, multidrug resistance, and low bioavailability. To 
overcome these challenges, many studies have focused on 
the structure-activity relationships. Investigations have 
improved some pharmaceutical properties of MTAs without 
significant problems (85).
The main purpose of effective cancer treatment is to 
improve the specificity of therapy and to reduce adverse 
effects, especially those limiting the dose. For example, 
CA-4 monotherapy has raised doubts due to metabolic 
vulnerability and conformational instability (86). It is 
important to reduce MTA toxicities against rapidly 
proliferating healthy cell compartments, such as 
haematological and gastrointestinal tissues.
Drug resistance is another major limitation. New 
targeted therapies and treatment approaches are being 
developed to overcome these limitations, including 
monoclonal antibodies (e. g. trastuzumab, bevacizumab), 
small molecule therapies (e. g. tyrosine kinase inhibitors, 
bortezomib), and drug conjugates. An example of the last 
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Figure 10 Structure of 2-methoxyestradiol (2ME2)
Figure 11 Structures of iso-ocobullenone [34] and bifidenone [35]
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group is vintafolide (EC 145), a water-soluble derivative 
of folic acid currently under evaluation in phase II clinical 
trials for the treatment of ovarian and lung cancer. It targets 
the upregulation of folate receptor (FR) expression. Folate 
receptors take three principal isoforms (α, β, and γ) with 
high affinity for folate-binding glycoproteins. FRα and FRβ 
strongly bind folic acid and its major circulating form 
5-methyltetrahydrofolate (MeTHF). FRα is expressed at 
very high levels in ovarian, lung, kidney, and breast cancer, 
and its expression is a negative prognostic factor in patients 
with ovarian, breast, endometrial, uterine, and colorectal 
cancer (83).
CURRENT CLINICAL TRIALS
Many new generation MTAs are still under evaluation 
for potential clinical use. Some of them have shown good 
tolerability and antitumor activity in specific cancers. 
ClinicalTrials.gov, a web-based resource established by the 
National Library of Medicine (NLM) of the National 
Institutes of Health (NIH), registered 5,662 ongoing and 
completed trials for various cancer treatments in 2018 
(Figure 12) (87).
Even though vinca alkaloids and taxanes have been 
known for 50 years, the scarcity of their natural sources 
(such as Pacific yew bark for taxol) is now being overcome 
by partial or total synthesis. However, total synthesis is still 
not the best option for development of drugs used in clinics. 
This situation is prevalent for many of the novel microtubule 
binding agents (88, 89). Tubulin inhibitors are generally 
used in combination with other chemotherapeutic drugs. 
Paclitaxel is commonly used with gemcitabine for the 
treatment of metastatic adenocarcinoma of the pancreas, 
while cabazitaxel is used with prednisone for the treatment 
of metastatic, hormone-resistant prostate cancer.
SCREENING SYSTEMS FOR MTAs
Screening systems, such as phenotypic screening and 
Biological Similarity Ensemble Approach (BIOSEA), 
screen large libraries of chemical compounds to help drug 
industry develop effective and safe drugs through new 
approaches that would bring some advantage over the 
currently available methods used in drug research and 
development.
Phenotypic screening
Phenotypic screening is used in drug discovery to 
identify molecules (in animal models or cell-based assays) 
that can alter cell phenotype. It does not rely on knowing 
specific drug target or its hypothetical role in the disease. 
This type of screening can capture complex biological 
mechanisms that escape other approaches. It provides the 
understanding of cell signalling networks in disease 
development and decreases the amount of clinical trial 
failures by identifying factors contributing to unexpected 
activity, toxicities, and lack of efficacy.
The enthusiasm for phenotypic screening as an 
alternative to target-focused small-molecule discovery has 
increased dramatically over the last few years. Phenotypic 
screening is based on the results of animal, cell-based, and 
disease-related phenotypic assays, which determine the 
phenotype of a physiological system. It also includes all 
preclinical assay formats that use animals, cells, and 
biochemical pathways. The aim is to identify molecules 
with specific biological effects that alter microtubule 
stability (90). Between 1999 and 2013; phenotypic 
screening has resulted in the discovery of 48 cancer drugs 
approved by the FDA, including three tubulin inhibitors 
(Table 1).
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Figure 12 Distribution of cancer types treated with MTAs in clinical trials [available from ClinicalTrials.gov (104)]
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Biological Similarity Ensemble Approach
Cortes Cabrera et al. (91) developed a statistical method 
called Biological Similarity Ensemble Approach (BIOSEA) 
to streamline the phenotypic screening workflow. This 
statistical method identifies molecules able to reproduce a 
desired cellular phenotype based on biological similarity 
with compounds with such effect. This method provided 
an advantage over high-throughput screening assays and 
overcame problems such as highly incomplete and noisy 
compound bioactivity. It helped identify novel nanomolar 
inhibitors of cell division that reproduce the action of 
reference natural products.
The last two decades have seen a dramatic change in 
the understanding of interactions between small molecules 
and biological systems. It came with a major shift from 
reductionism to a more pragmatic view of living organisms 
as complex entities. At the same time phenotypic screening 
brought new challenges, such as the identification of 
mechanisms of action and effective targets responsible for 
these phenotypes. BIOSEA allows phenotypic screening 
without the need for information about the chemical 
structure of the target or associated ligands. One example 
is the Na-K-Cl cotransporter (NKCC1) (91). Its cellular 
phenotype was characterised, and well-known natural 
products that inhibit cell division in two different ways, 
namely paclitaxel as a microtubule-stabilising agent and 
one tubulin polymerisation inhibitor, were selected as 
references to predict biologically similar compounds that 
could arrest the cell cycle.
In short, this statistical method establishes new 
relationships between targets and small molecules, which 
streamlines drug discovery.
CONCLUSION
Continuing research on the mechanisms of action of 
MTAs, discovery of new drugs, and search for novel therapy 
strategies helps to reduce their adverse effects, overcome 
resistance to cancer therapy, and provide more effective 
therapeutic options for cancer patients. This cannot be 
achieved without a better understanding of the molecular 





1. Chabner BA, Roberts TG Jr. Timeline: Chemotherapy and 
the war on cancer. Nat Rev Cancer 2005;5:65–72. doi: 
10.1038/nrc1529
2. World Health Organization (WHO). Cancer, Fact sheet 
February 2017 [displayed 9 September 2019]. Available at 
https://www.who.int/news-room/fact-sheets/detail/cancer
3. Kumar S, Ahmad MK, Waseem M, Pandey AK. Drug targets 
for cancer treatment: an overview. Med Chem 2015;5:115–
23. doi: 10.4172/2161-0444.1000252
4. Poruchynsky MS, Komlodi-Pasztor E, Trostel S, Wilkerson 
J, Regairaz M, Pommier Y, Zhang X, Kumar Maity T, Robey 
R, Burotto M, Sackett D, Guha U, Fojo AT. Microtubule-
targeting agents augment the toxicity of DNA-damaging 
agents by disrupting intracellular trafficking of DNA repair 
proteins. Proc Natl AcadSci U S A 2015;112:1571–6. doi: 
10.1073/pnas.1416418112
5. Giavazzi R, Bonezzi K, Taraboletti G. Microtubule targeting 
agents and the tumor vasculature. In: Fojo AT, editor. The 
role of microtubules in cell biology, neurobiology, and 
oncology. Totowa (NJ). Humana Press; 2008. p. 519–30.
6. Jordan MA, Wilson L. Microtubules as a target for anticancer 
drugs. Nat Rev Cancer 2004;4:253–65. doi: 10.1038/nrc1317
7. Dong M, Liu F, Zhou H, Zhai S, Yan B. Novel natural product 
and privileged scaffold-based tubulin inhibitors targeting the 
colchicine binding site. Molecules 2016;21:1375. doi: 
10.3390/molecules21101375
Karahalil B, Yardım-Akaydin S, Nacak Baytas S. An overview of microtubule targeting agents for cancer therapy 
Arh Hig Rada Toksikol 2019;70:160-172





















Taxane analogue selected 








Synthetic analogue of 
natural product from 
cytotoxicity screen; 








Targeted M Microtubule stabiliser
Rationally designed 
epothilone analogue; 
parent drug discovered 
by phenotypic cytotoxic 
screening.
3 T/M –tubulin/microtubules; MOA –mechanism of action
169 Karahalil B, Yardım-Akaydin S, Nacak Baytas S. An overview of microtubule targeting agents for cancer therapy Arh Hig Rada Toksikol 2019;70:160-172
8. Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, 
Haber M, Horwitz SB. Taxol-resistant epithelial ovarian 
tumors are associated with altered expression of specific 
beta-tubulin isotypes. J Clin Invest 1997;100:1282–93. doi: 
10.1172/JCI119642
9. Forli S. Epothilones: from discovery to clinical trials. Curr 
Top Med Chem 2014;14:2312–21. doi: 10.2174/156802661
4666141130095855
10. Crimmins MT. Synthetic approaches to the microtubule 
stabilizing agent (-)-laulimalide. Curr Opin Drug Discov 
Devel 2002;5:944–59. PMID: 12478725
11. Steinmetz MO, Prota AE. Microtubule-targeting agents: 
strategies to hijack the cytoskeleton. Trends Cell Biol 
2018;28:776–92. doi: 10.1016/j.tcb.2018.05.001
12. Sapra S, Bhalla Y, Sharma S, Singh G, Nepali K, Budhiraja 
A, Dhar KL. Colchicine and its various physicochemical and 
biological aspects. Med Chem Res 2013;22:531–47. doi: 
10.1007/s00044-012-0077-z
13. Jain S, Vahdat LT. Eribulinmesylate. Clin Cancer Res 
2011;17:6615–22. doi: 10.1158/1078-0432.CCR-11-1807
14. Modrianský M, Dvorák Z. Microtubule disruptors and their 
interaction with biotransformation enzymes. Biomed Pap 
Med Fac Univ Palacky Olomouc Czech Repub 2005;149:213–
5. doi: 10.5507/bp.2005.028
15. Dumontet C, Jordan MA. Microtubule-binding agents: a 
dynamic field of cancer therapeutics. Nat Rev Drug Discov 
2010;9:790–803. doi: 10.1038/nrd3253
16. Prota AE, Bargsten K, Zurwerra D, Field JJ, Díaz JF, Altmann 
KH, Steinmetz MO. Molecular mechanism of action of 
microtubule-stabilizing anticancer agents. Science 
2013;339:587–90. doi: 10.1126/science.1230582
17. Pryor DE, O’Brate A, Bilcer G, Díaz JF, Wang Y, Wang Y, 
Kabaki M, Jung MK, Andreu JM, Ghosh AK, Giannakakou 
P, Hamel E. The microtubule stabilizing agent laulimalide 
does not bind in the taxoid site, kills cells resistant to 
paclitaxel and epothilones, and may not require its epoxide 
moiety for activity. Biochemistry 2002;41:9109–15. doi: 
10.1021/bi020211b
18. Prota AE, Bargsten K, Northcote PT, Marsh M, Altmann KH, 
Miller JH, Díaz JF, Steinmetz MO. Structural basis of 
microtubule stabilization by laulimalide and peloruside A. 
Angew Chem Int Ed Engl 2014;53:1621–5. doi: 10.1002/
anie.201307749
19. Pellegrini F. Review: Tubulin function, action of antitubulin 
drugs and new drug development. Cancer Invest 2005;23:264–
73. doi: 10.1081/CNV-200055970
20. Ley CD, Horsman MR, Kristjansen PE. Early effects of 
combretastatin-A4 disodium phosphate on tumor perfusion 
and interstitial fluid pressure. Neoplasia 2007;9:108–12. doi: 
10.1593/neo.06733
21. Gutiérrez ST, Díaz-Oltra S, Falomir E, Murga J, Cardaa M, 
Marco JA. Synthesis of combretastatin A-4 O-alkyl 
derivatives and evaluation of their cytotoxic, antiangiogenic 
and antitelomerase activity. Bioorg Med Chem 2013;21:7267–
74. doi: 10.1016/j.bmc.2013.09.064
22. Ohsumi K, Hatanaka T, Fujita K, Nakagawa R, Fukuda Y, 
Nihei Y, Suga Y, Morinaga Y, Akiyama Y, Tsuji T. Syntheses 
and antitumor activity of cis-restricted combretastatins, 
5-membered heterocyclic analogues. Bioorg Med Chem Lett 
1998;8:3153–8. doi: 10.1016/s0960-894x(98)00579-4
23. Yang T, Wang Y, Li Z, Dai W, Yin J, Liang L, Ying X, Zhou 
S, Wang J, Zhang X, Zhang Q. Targeted delivery of a 
combination therapy consisting of combretastatin A4 and 
low-dose doxorubicin against tumorneovasculature. 
Nanomed ic ine  2012 ;8 :81–92 .  do i :  10 .1016 / j .
nano.2011.05.003
24. Gao M, Zhang D, Jin Q, Jiang C, Wang C, Li J, Peng F, Huang 
D, Zhang J, Song S. Combretastatin-A4 phosphate improves 
the distribution and antitumor efficacy of albumin-bound 
paclitaxel in W256 breast carcinoma model. Oncotarget 
2016;7:58133–41. doi: 10.18632/oncotarget.11249
25. Abma E, Daminet S, Smets P, Ni Y, de Rooster H. 
Combretastatin A4-phosphate and its potential in veterinary 
oncology, a review. Vet Comp Oncol 2017;15:184–93. doi: 
10.1111/vco.12150
26. Marzo-Mas A, Barbier P, Breuzard G, Allegro D, Falomir E, 
Murga J, Carda M, Peyrot V, Marco JA. Interactions of long-
chain homologues of colchicine with tubulin. Eur J Med 
Chem 2017;126:526–35. doi: 10.1016/j.ejmech.2016.11.049
27. Ahmed RI, Osman EE, Awadallah FM, El-Moghazy SM. 
Design, synthesis and molecular docking of novel 
diarylcyclohexenone and diarylindazole derivatives as 
tubulin polymerization inhibitors. J Enzyme Inhib Med Chem 
2017;32:176–88. doi: 10.1080/14756366.2016.1244532
28. De Martino G, La Regina G, Coluccia A, Edler MC, Barbera 
MC, Brancale A, Wilcox E, Hamel E, Artico M, Silvestri R. 
Arylthioindoles, potent inhibitors of tubulin polymerization. 
J Med Chem 2004;47:6120–3. doi: 10.1021/jm049360d
29. Tantak MP, Wang J, Singh RP, Kumar A, Shah K, Kumar D. 
2-(3’-Indolyl)-N-arylthiazole-4-carboxamides: Synthesis and 
evaluation of antibacterial and anticancer activities. Bioorg 
Med Chem Lett 2015;25:4225–31. doi: 10.1016/j.
bmcl.2015.07.105
30. Kamath PR, Sunil D, Ajees AA, Pai KS, Das S. Some new 
indole-coumarin hybrids; Synthesis, anticancer and Bcl-2 
docking studies. Bioorg Chem 2015;63:101–9. doi: 
10.1016/j.bioorg.2015.10.001
31. Das Mukherjee D, Kumar NM, Tantak MP, Das A, Ganguli 
A, Datta S, Kumar D, Chakrabarti G. Development of novel 
bis(indolyl)-hydrazide-hydrazone derivatives as potent 
microtubule-targeting cytotoxic agents against A549 lung 
cancer cells. Biochemistry 2016;55:3020–35. doi: 10.1021/
acs.biochem.5b01127
32. Liu Y-M, Chen H-L, Lee H-Y, Liou J-P. Tubulin inhibitors: 
a patent review. Expert OpinTher Pat 2014;24:69–88. doi: 
10.1517/13543776.2014.859247
33. Ramya PVS, Guntuku L, Angapelly S, Digwal CS, Lakshmi 
UJ, Sigalapalli DK, Babu BN, Naidu VGM, Kamal A. 
Synthesis and biological evaluation of curcumin inspired 
indole analogues as tubulin polymerization inhibitors. Eur J 
Med  Chem 2017;127 :100–14 .  do i :  10 .1016 / j .
ejmech.2016.12.043
34. Zhang YL, Qin YJ, Tang DJ, Yang MR, Li BY, Wang YT, 
Cai HY, Wang BZ, Zhu HL. Synthesis and biological 
evaluation of 1-methyl-1H-indole-pyrazoline hybrids as 
potential tubulin polymerization inhibitors. Chem Med Chem 
2016;11:1446–58. doi: 10.1002/cmdc.201600137
35. Wang YT, Cai XC, Shi TQ, Zhang YL, Wang ZC, Liu CH, 
Zhu HL. Synthesis, molecular docking and biological 
evaluation of 1-phenylsulphonyl-2-(1-methylindol-3-yl)-
benzimidazole derivatives as novel potential tubulin 
assembling inhibitors. Chem Biol Drug Des 2017;90:112–8. 
doi: 10.1111/cbdd.12932
170
36. Guggilapu SD, Lalita G, Reddy TS, Prajapti SK, Nagarsenkar 
A, Ramu S, Brahma UR, Lakshmi UJ, Vegi GMN, Bhargava 
SK, Babu BN. Synthesis of C5-tethered indolyl-3-
glyoxylamide derivatives as tubulin polymerization 
inhibitors. Eur J Med Chem 2017;28:1–12. doi: 10.1016/j.
ejmech.2017.01.026
37. Chennamaneni S, Gan C, Lama R, Zhong B, Su B. 
Indomethacin derivatives as tubulin stabilizers to inhibit 
cancer cell proliferation. Bioorg Med Chem 2016;24:277–85. 
doi: 10.1016/j.bmc.2015.12.016
38. Baytas SN, Inceler N, Yilmaz A, Olgac A, Menevse S, 
Banoglu E, Hamel E, Bortolozzi R, Viola G. Synthesis, 
biological evaluation and molecular docking studies of trans-
indole-3-acrylamide derivatives, a new class of tubulin 
polymerization inhibitors. Bioorg Med Chem 2014;22:3096–
104. doi: 10.1016/j.bmc.2014.04.027
39. Ghinet A, Moise IM, Rigo B, Homerin G, Farce A, Dubois 
J, Bîcu E. Studies on phenothiazines, new microtubule-
interacting compounds with phenothiazine A-ring as potent 
antineoplastic agents. Bioorg Med Chem 2016;24:2307–17. 
doi: 10.1016/j.bmc.2016.04.001
40. Ali I, Lone MN, Al-Othman ZA, Al-Warthan A, Sanagi MM. 
Heterocyclic scaffolds: centrality in anticancer drug 
development. Curr Drug Targets 2015;16:711–34. doi: 10.2
174/1389450116666150309115922
41. Singh S, Ahmad A, Raghuvanshi DS, Hasanain M, Agarwal 
K, Dubey V, Fatima K, Alam S, Sarkar J, Luqman S, Khan 
F, Tandon S, Gupta A. Synthesis of 3,5-dihydroxy-7,8-
dimethoxy-2-(4-methoxyphenyl)benzopyran-4-one 
derivatives as anticancer agents. Bioorg Med Chem Lett 
2016;26:5322–7. doi: 10.1016/j.bmcl.2016.09.036
42. Andújar I, Ríos JL, Giner RM, Recio MC. Pharmacological 
properties of shikonin - a review of literature since 2002. 
Planta Med 2013;79:1685–97. doi: 10.1055/s-0033-1350934
43. Andújar I, Ríos JL, Giner RM, Recio MC. Shikonin promotes 
intestinal wound healing in vitro via induction of TGF-β 
release in IEC-18 cells. Eur J Pharm Sci 2013;49:637–41. 
doi: 10.1016/j.ejps.2013.05.018
44. Huang CS, Lin AH, Yang TC, Liu KL, Chen HW, Lii CK. 
Shikonin inhibits oxidized LDL-induced monocyte adhesion 
by suppressing NFκB activation via up-regulation of PI3K/
Akt/Nrf2-dependent antioxidation in EA.hy926 endothelial 
cells. Biochem Pharmacol 2015;93:352–61. doi: 10.1016/j.
bcp.2014.12.005
45. Skrzypczak A, Przystupa N, Zgadzaj A, Parzonko A, 
Sykłowska-Baranek K, Paradowska K, Nałęcz-Jawecki G. 
Antigenotoxic, anti-photogenotoxic and antioxidant activities 
of natural naphthoquinone shikonin and acetylshikonin and 
Arnebiaeuchroma callus extracts evaluated by the umu-test 
and EPR method. Toxicol In Vitro 2015;30:364–72. doi: 
10.1016/j.tiv.2015.09.029
46. Liang D, Sun Y, Shen Y, Li F, Song X, Zhou E, Zhao F, Liu 
Z, Fu Y, Guo M, Zhang N, Yang Z, Cao Y. Shikonin exerts 
anti-inflammatory effects in a murine model of 
lipopolysaccharide-induced acute lung injury by inhibiting 
the nuclear  factor-kappa B signal ing pathway. 
IntImmunopharmacol 2013;16:475–80. doi: 10.1016/j.
intimp.2013
47. Liu J, Wang P, Xue YX, Li Z, Qu CB, Liu YH. Enhanced 
antitumor effect of shikonin by inhibiting Endoplasmic 
Reticulum Stress via JNK/c-Jun pathway in human 
glioblastoma stem cells. Biochem Biophys Res Commun 
2015;466:103–10. doi: 10.1016/j.bbrc.2015.08.115
48. Qiu HY, Wang F, Wang X, Sun WX, Qi JL, Pang YJ, Yang 
RW, Lu GH, Wang XM, Yang YH. Design, synthesis, and 
biological evaluation of chalcone-containing shikonin 
derivatives as inhibitors of tubulin polymerization. Chem 
Med Chem 2017;12:399–406. doi: 10.1002/cmdc.201700001
49. Kamal A, Srikanth YV, Naseer Ahmed Khan M, Ashraf M, 
Kashi Reddy M, Sultana F, Kaur T, Chashoo G, Suri N, Sehar 
I, Wani ZA, Saxena A, Sharma PR, Bhushan S, Mondhe DM, 
Saxena AK. 2-Anilinonicotinyl linked 2-aminobenzothiazoles 
and [1,2,4]triazolo[1,5-b] [1,2,4]benzothiadiazine conjugates 
as potential mitochondrial apoptotic inducers. Bioorg Med 
Chem 2011;19:7136–50. doi: 10.1016/j.bmc.2011.09.060
50. Kamal A, Hussaini SM, Nayak VL, Malik MS, Sucharitha 
ML, Shaik TB, Ashraf M, Bagul C. Synthesis of 
2-anilinopyridine dimers as microtubule targeting and 
apoptosis inducing agents. Bioorg Med Chem 2014;22:6755–
67. doi: 10.1016/j.bmc.2014.11.001
51. Kamal A, Khan MN, Srinivasa Reddy K, Rohini K. Synthesis 
o f  a  n e w  c l a s s  o f  2 - a n i l i n o  s u b s t i t u t e d 
nicotinylarylsulfonylhydrazides as potential anticancer and 
antibacterial agents. Bioorg Med Chem 2007;15:1004–13. 
doi: 10.1016/j.bmc.2006.10.027
52. Dorléans A, Gigant B, Ravelli RB, Mailliet P, Mikol V, 
Knossow M. Variations in the colchicine-binding domain 
provide insight into the structural switch of tubulin. Proc Natl 
Acad Sci USA 2009;106:13775–9. doi: 10.1073/
pnas.0904223106
53. Elmeligie S, Khalil NA, Ahmed EM, Emam SH. New 
3-substituted-2-(4-hydroxyanilino) pyridine derivatives, 
synthesis, antitumor activity and tubulin polymerization 
inhibition. Arch Pharm (Weinheim) 2017;350(2):e1600256. 
doi: 10.1002/ardp.201600256
54. Liu YN, Wang JJ, Ji YT, Zhao GD, Tang LQ, Zhang CM, 
Guo XL, Liu ZP. Design, synthesis and biological evaluation 
of 1 methyl-1,4-dihydroindeno[1,2-c]pyrazole analogues as 
potential anticancer agents targeting tubulin colchicine 
binding site. J Med Chem 2016;59:5341–55. doi: 10.1021/
acs.jmedchem.6b00071
55. Ali I, Haque A, Saleem K, Hsieh MF. Curcumin-I 
Knoevenagel’s condensates and their Schiff’s bases as 
anticancer agents: synthesis, pharmacological and simulation 
studies. Bioorg Med Chem 2013;21:3808–20. doi: 10.1016/j.
bmc.2013.04.018
56. Saleem K1, Wani WA, Haque A, Lone MN, Hsieh MF, 
Jairajpuri MA, Ali I. Synthesis, DNA binding, hemolysis 
assays and anticancer studies of copper(II), nickel(II) and 
iron(III) complexes of a pyrazoline-based ligand. Future Med 
Chem 2013;5:135–46. doi: 10.4155/fmc.12.201
57. Magalhaes LG, Marques FB, da Fonseca MB, Rogério KR, 
Graebin CS, Andricopulo AD. Discovery of a series of 
acridinones as mechanism-based tubulin assembly inhibitors 
with anticancer activity. Plos One 2016;11(8):e0160842. doi: 
10.1371/journal.pone.0160842
58. Devambatla RK, Namjoshi OA, Choudhary S, Hamel E, 
Shaffer CV, Rohena CC, Mooberry SL, Gangjee A. Design, 
synthesis, and preclinical evaluation of 4 substituted-5-
methyl-furo[2,3-d]pyrimidines as microtubule targeting 
agents that are effective against multidrug resistant cancer 
cells. J Med Chem 2016;59:5752–65. doi: 10.1021/acs.
jmedchem.6b00237
Karahalil B, Yardım-Akaydin S, Nacak Baytas S. An overview of microtubule targeting agents for cancer therapy 
Arh Hig Rada Toksikol 2019;70:160-172
171
59. Mollinedo F, Gajate C. Microtubules, microtubule-interfering 
agents and apoptosis. Apoptosis 2003;8:413–50. doi: 
10.1023/A:1025513106330
60. Zhou J, Giannakakou P. Targeting microtubules for cancer 
chemotherapy. Curr Med Chem Anticancer Agents 
2005;5:65–71. doi: 10.2174/1568011053352569
61. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule 
assembly in vitro by taxol. Nature 1979;277:665–7. doi: 
10.1016/j.ab.2006.10.014
62. Buey RM, Barasoain I, Jackson E, Meyer A, Giannakakou 
P, Paterson I, Mooberry S, Andreu JM, Díaz JF. Microtubule 
interactions with chemically diverse stabilizing agents, 
thermodynamics of binding to the paclitaxel site predicts 
cytotoxicity. Chem Biol 2005;12:1269–79. doi: 10.1016/j.
chembiol.2005.09.010
63. Kingston DGI, Jagtap PG, Yuan H, Samala L. The chemistry 
of taxol and related taxoids. In: Herz W, Falk H, Kirby GW, 
editors. Progress in the chemistry of organic natural products. 
Vol. 84. Wien: Springer; 2002. p. 53–225.
64. Wang Y, Wang J, Wang H, Ye W. Novel taxane derivatives 
from Taxus wallichiana with high anticancer potency on 
tumor cells. Chem Biol Drug Des 2016;88:556–61. doi: 
10.1111/cbdd.12782
65. Barbier P, Tsvetkov PO, Breuzard G, Devred F. Deciphering 
the molecular mechanisms of anti-tubulin plant derived 
drugs. Phytochem Rev 2014;13:157–69. doi: 10.1007/
s11101-013-9302-8
66. Verma K, Kannan K, Shanthi V, Sethumadhavan R, Karthick 
V, Ramanathan K. Exploring β-tubulin inhibitors from plant 
origin using computational approach. Phytochem Anal 
2017;28:230–41. doi: 10.1002/pca.2665
67. Busch T, Kirschning A. Recent advances in the total synthesis 
of pharmaceutically relevant diterpenes. Nat Prod Rep 
2008;25:318–41. doi: 10.1039/b705652b
68. Pfeffer TJ, Sasse F, Schmidt CF, Lakämper S, Kirschning A, 
Scholz T. The natural diterpenetonantzitlolone A its synthetic 
enantiomer inhibits cell proliferation and kinesin-5 function. 
Eur J Med Chem 2016;112:164–70. doi: 10.1016/j.
ejmech.2016.02.022
69. Lee YJ, Lee YM, Lee CK, Jung JK, Han SB, Hong JT. 
Therapeutic applications of compounds in the Magnolia 
family. Pharmacol Ther 2011;130:157–76. doi: 10.1016/j.
pharmthera.2011.01.010
70. Hwang ES, Park KK. Magnolol suppresses metastasis via 
inhib i t ion  of  invas ion ,  migra t ion ,  and  mat r ix 
metalloproteinase-2/-9 activities in PC-3 human prostate 
carcinoma cells. Biosci Biotechnol Biochem 2010;74:961–7. 
doi: 10.1271/bbb.90785
71. Kang YJ, Park HJ, Chung HJ, Min HY, Park EJ, Lee MA, 
Shin Y, Lee SK. Wnt/β-catenin signaling mediates the 
antitumor activity of magnolol in colorectal cancer cells. Mol 
Pharmacol 2012;82:168–77. doi: 10.1124/mol.112.078535
72. Li ML, Zhang F, Wang XA, Wu XS, Zhang BT, Zhang N, 
Wu WG, Wang Z, Weng H, Liu SB, Gao GF, Mu JS, Shu YJ, 
Bao RF, Cao Y, Lu JH, Gu J, Zhu J, Liu YB. Magnolol inhibits 
growth of gallbladder cancer cells through the p53 pathway. 
Cancer Sci 2015;106:1341–50. doi: 10.1111/cas.12762
73. Shen J, Ma H, Zhang T, Liu H, Yu L, Li G, Li H, Hu M. 
Magnolol inhibits the growth of non-small cell lung cancer 
via inhibiting microtubule polymerization. Cell Physiol 
Biochem 2017;42:1789–801. doi: 10.1159/000479458
74. Wu W-N, Beal JL, Doskotch RW. Alkaloids of thalictrum 
XXX. Eleven minor alkaloids from Thalictrum rugosum. J 
Nat Prod 1980;43:143–50. doi: 10.1021/np50007a014
75. Levrier C, Rockstroh A, Gabrielli B, Kavallaris M, Lehman 
M, Davis RA, Sadowski MC, Nelson CC. Discovery of 
thalicthuberine as a novel antimitotic agent from nature that 
disrupts microtubule dynamics and induces apoptosis in 
prostate cancer cells. Cell Cycle 2018;17:652–68. doi: 
10.1080/15384101.2017.1356512
76. Levrier C, Sadowski MC, Nelson CC, Davis RA. Cytotoxic 
C20diterpenoid alkaloids from the Australian endemic 
rainforest plant Anopterusmacleayanus. J Nat Prod 
2015;78:2908–16. doi: 10.1021/acs.jnatprod.5b00509
77. Levrier C, Sadowski MC, Rockstroh A, Gabrielli B, 
Kavallaris M, Lehman M, Davis RA, Nelson CC. 
6α-acetoxyanopterine, a novel structure class of mitotic 
inhibitor disrupting microtubule dynamics in prostate cancer 
cells. Mol Cancer Ther 2017;16:3–15. doi: 10.1158/1535-
7163.MCT-16-0325
78. Williams RB, Martin SM, Lawrence JA, Norman VL, O’Neil-
Johnson M, Eldridge GR, Starks CM. Isolation and 
identification of the novel tubulin polymerization inhibitor 
bifidenone. J Nat Prod 2017;80:616–24. doi: 10.1021/acs.
jnatprod.6b00893
79. Mukhtar E, Mustafa Adhami V, Mukhtar H. Targeting 
microtubules by natural agents for cancer therapy. Mol 
Cancer Ther 2014;13:275–84. doi: 10.1158/1535-7163.MCT-
13-0791
80. Soto E, Keizer RJ, Trocóniz IF, Huitema AD, Beijnen JH, 
Schellens JH, Wanders J, Cendrós JM, Obach R, Peraire C, 
Friberg LE, Karlsson MO. Predictive ability of a semi-
mechanistic model for neutropenia in the development of 
novel anti-cancer agents: two case studies. Invest New Drugs 
2011;29:984–95. doi: 10.1007/s10637-010-9437-z
81. Cheng KL, Bradley T, Budman DR. Novel microtubule-
targeting agents - the epothilones. Biologics 2008;2:789–811. 
PMCID: PMC2727900
82. Baas PW, Ahmad FJ. Beyond taxol: microtubule-based 
treatment of disease and injury of the nervous system. Brain 
2013;136:2937–51. doi: 10.1093/brain/awt153
83. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J 
M e d  1 9 9 5 ; 3 3 2 : 1 0 0 4 – 1 4 .  d o i :  1 0 . 1 0 5 6 /
NEJM199504133321507
84. Lee JJ, Swain SM. Peripheral neuropathy induced by 
microtubule-stabilizing agents. J Clin Oncol 2006;24:1633–
42. doi: 10.1200/JCO.2005.04.0543
85. Ying Z, Xin M, Guanhua D. Microtubule-stabilizing agents: 
New drug discovery and cancer therapy. Pharmacol Therap 
2016;162:134–43. doi: 10.1016/j.pharmthera.2015.12.006
86. Tarade D, Pandey S, McNulty J. Review of cytotoxic CA4 
analogues that do not target microtubules, implications for 
CA4 development. Mini Rev Med Chem 2017;17:1507–14. 
doi: 10.2174/1389557515666160509125829
87. US National Library of Medicine (NLM). ClinicalTrials.gov 
[displayed 10 September 2019]. Available at https://
clinicaltrials.gov/ct2/results?term=tubulin+inhibitors
88. de Lemos E, Porée FH, Bourin A, Barbion J, Agouridas E, 
Lannou MI, Commerçon A, Betzer JF, Pancrazi A, Ardisson 
J. Total synthesis of discodermolide, optimization of the 
effective synthetic route. Chemistry 2008;14:11092–112. doi: 
10.1002/chem.200801478
Karahalil B, Yardım-Akaydin S, Nacak Baytas S. An overview of microtubule targeting agents for cancer therapy 
Arh Hig Rada Toksikol 2019;70:160-172
172
Pregled lijekova protiv raka koji ciljano djeluju na mikrotubule
U cijelome se svijetu traga za djelotvornim liječenjem protiv raka čije bi koristi prevagnule nad štetnim djelovanjem. 
Jedan od načina da se smanji otpornost na kemoterapiju i njezine štetne učinke svakako je takozvano ciljano liječenje, 
usmjereno na pojedine molekule (molekulske ciljeve) koje imaju važnu ulogu u rastu, napredovanju i metastaziranju raka. 
Primjer takvih specifičnih ciljeva su mikrotubuli. U ovom se preglednom radu osvrćemo na najnovije spoznaje o lijekovima 
koji ciljano djeluju na mikrotubule (engl. microtubule-targeting agents/drugs, krat. MTA/MTD), a rabe se u liječenju 
raka. Takvi prirodni i sintetizirani lijekovi djeluju protutumorski, a pretklinička istraživanja i klinička ispitivanja pokazuju 
da je njihova djelotvornost veća nego ona tradicionalnih lijekova. Osim toga, ti lijekovi donose manji rizik od štetnih 
učinaka poput neurotoksičnosti i hemotoksičnosti. Upravo se klinički ocjenjuju nove generacije nekoliko lijekova koji 
ciljano djeluju na mikrotubule. Ovdje donosimo najnovije spoznaje o njihovim koristima, pristupima liječenju, prednostima 
i izazovima u istraživanju.
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